Renalys Pharma closes ¥6.0Bn series A financing to advance kidney disease treatments across Asia
Amount Raised
¥6 Billion
Round Type
Series A
TokyoBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharmaInvestors
Description
Renalys Pharma, Inc., a late-stage clinical biopharmaceutical company has completed a ¥6.0Bn Series A financing co-led by Catalys Pacific and SR One, along with additional investors, including JPS Growth Investment Limited Partnership, Sumitomo Mitsui Trust Bank Co., Ltd., Japan Co-Invest IV Limited Partnership, NVCC NO.9 Investment Limited Partnership. The funding will drive the development of Sparsentan for IgA nephropathy in Japan and other Asian countries, enabling the completion of Phase III clinical trial for Sparsentan in Japan.
Quick answer
Renalys Pharma raised ¥6 Billion in a Series A round, dated July 17, 2024. Investors: Nvcc No.9 Investment Limited Partnership, Japan Co Invest Iv Limited Partnership, Sumitomo Mitsui Trust Bank Co., Ltd., JPS Growth Investment Limited Partnership, SR One and Catalys Pacific. Renalys Pharma is based in Tokyo, Tokyo, Japan.
- How much did Renalys Pharma raise?
- Renalys Pharma raised ¥6 Billion in a Series A round on July 17, 2024.
- Who invested in Renalys Pharma?
- Nvcc No.9 Investment Limited Partnership, Japan Co Invest Iv Limited Partnership, Sumitomo Mitsui Trust Bank Co., Ltd., JPS Growth Investment Limited Partnership, SR One and Catalys Pacific are named as investors in this round.
- What does Renalys Pharma do?
- Renalys Pharma, Inc. is a privately held late-stage clinical biopharmaceutical company based in Japan.
- Where is Renalys Pharma based and how big is it?
- Renalys Pharma is based in Tokyo, Tokyo, Japan.
- Who are the decision-makers at Renalys Pharma?
- Fundz holds 1 contact at Renalys Pharma. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Pharmaceutical around the same time
Companies in the same sectors as Renalys Pharma that raised within 45 days of this round, from Fundz verified event records.
- Pathalys Pharma raised $105M (Series B) on August 21, 2024.
- Retension Pharmaceuticals raised $10M (Series A) on August 21, 2024.
- Lipella Pharmaceuticals raised $120K on July 31, 2024.
- Ensho Therapeutics raised $400K on July 19, 2024.
- CASI Pharmaceuticals raised $15M (Post-IPO Equity) on June 26, 2024.
- CASI Pharmaceuticals raised $15M on June 26, 2024.
Who to call at Renalys Pharma, and when
A new round usually means Renalys Pharma is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Renalys Pharma raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Renalys Pharma, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Renalys Pharma. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Renalys Pharma raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansRenalys Pharma raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.